R emote ischemic conditioning (RIC) is a phenomenon where nonlethal ischemic exposure in a peripheral tissue induces a systemic protection of subsequent injuries in distant organs and tissues. 1 RIC has shown encouraging results in animal models by providing cardio-and neuroprotective effects against an ischemic injury, and thus RIC is emerging as an attractive novel therapeutic for clinical trials. [2] [3] [4] Recent human studies have confirmed the safety and feasibility of lower limb RIC in patients with aneurysmal subarachnoid hemorrhage (aSAH). 5, 6 Based on our separate study (Laiwalla et al, unpublished data), the odds ratio of a good outcome for patients with RIC is 5.17 (95% confidence interval, 1.21-25.02) when compared with matched controls with SAH.
The effectiveness of RIC is likely to be caused by its multifactorial effects, and rodent studies suggest that these are mediated in part by a cascade of transcriptional and translational changes. 7 Activation of basic cell survival responses to transient ischemia causes a shift toward a protective genetic profile, leading to a differential regulation of genes involved in inflammation, neurotransmitter excitotoxicity, apoptosis, and cerebrovascular perfusion. [8] [9] [10] [11] [12] [13] Nevertheless, the mechanisms by which RIC provides neuroprotective effects in human are not well understood. The involvement of humoral factors has been demonstrated in animals because the protection can be transferred from an RIC animal to a nonconditioned animal by whole blood transfusion.
14 Thus, genetic and epigenetic studies in human blood could elucidate the humeral processes catalyzed by RIC and furthermore provide potential diagnostic and therapeutic targets for the treatment and prevention of ischemic injury.
Background and Purpose-Remote ischemic conditioning (RIC) is a phenomenon in which short periods of nonfatal ischemia in 1 tissue confers protection to distant tissues. Here we performed a longitudinal human pilot study in patients with aneurysmal subarachnoid hemorrhage undergoing RIC by limb ischemia to compare changes in DNA methylation and transcriptome profiles before and after RIC. Methods-Thirteen patients underwent 4 RIC sessions over 2 to 12 days after rupture of an intracranial aneurysm. We analyzed whole blood transcriptomes using RNA sequencing and genome-wide DNA methylomes using reduced representation bisulfite sequencing, both before and after RIC. We tested differential expression and differential methylation using an intraindividual paired study design and then overlapped the differential expression and differential methylation results for analyses of functional categories and protein-protein interactions. Results-We observed 164 differential expression genes and 3493 differential methylation CpG sites after RIC, of which 204 CpG sites overlapped with 103 genes, enriched for pathways of cell cycle (P<3.8×10 −4 ) and inflammatory responses (P<1.4×10
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In this human pilot study, we performed a prospective longitudinal evaluation in a group of patients with aSAH undergoing RIC to study the induced genomic responses by identifying and comparing blood DNA methylation and gene expression profiles before RIC and 1 week after RIC. Identification of factors altered by a transient limb RIC can provide insights into the mechanisms of neuroprotective action and, ultimately, may yield biomarkers for SAH prognosis and treatment.
Methods
Study Samples
Patients with aSAH were enrolled from the Remote Ischemic Preconditioning in Subarachnoid Hemorrhage Trial (Clinicaltrials. gov No. NCT01158508). The study was approved by the local institutional review board, and all participants gave a written informed consent. Patients 18 to 80 years old with SAH confirmed by computed tomography or lumbar puncture and presence of a ruptured intracranial aneurysm confirmed by computed tomography, magnetic resonance, or catheter angiography were considered for enrollment in this study. Patients who were pregnant or with a history or physical examination findings of peripheral vascular disease, deep venous thrombosis, peripheral neuropathy, or lower extremity bypass were excluded. Clinical characteristics are provided in Table 1 .
RIC Protocol
Patients underwent 4 RIC sessions over 2 to 12 days after aneurysm rupture. RIC sessions were performed on the lower limb with a large adultsized blood pressure cuff. Each session consisted of 4 inflation cycles lasting 5 minutes, followed by 5-minute deflations. Cuff pressure was originally inflated at 20 mm Hg over the patient's baseline systolic blood pressure, then increased until the dorsalis pedis pulse was abolished, as confirmed by a Doppler ultrasonography. This pressure was maintained for 5 minutes throughout the duration of the inflation cycle.
Peripheral blood samples were drawn from aSAH patients at 2 different time points: before RIC (baseline) and after 4 sessions of the RIC treatment. DNA and RNA were isolated according to standard protocols.
Aneurysm Controls
We included 24 control individuals with a history of intracranial aneurysms who never received RIC treatment. The blood collection and sample processing were performed in the same way as described for the aSAH cases above.
RNA Sequencing
We included 13 aSAH sample pairs and 24 aneurysm controls in the study after the initial quality control of the blood RNA (RNA integrity number [RIN] value >7, RNA concentration >10 ng/μL). The blood RNA sequencing libraries were prepared using Illumina TruSeq RNA library kit, and sequencing of the paired-end, 100-bp reads was performed using the Illumina Hiseq2000 platform, resulting in on average 46.1 mol/L reads per sample. We used STAR 15 to align the fastq files to the human GRCh37/hg19 reference genome with the following settings: the maximum intron size was set at 500 kb; the minimum intron size was set at 20; and we allowed for 4 mismatches. We used HTSeq (version HTSeq-0.6.1) 16 to produce raw counts.
Differential Expression Using EdgeR and DESeq2
We used both EdgeR 17 and DESeq2 18 R-packages to identify differentially expressed (DE) genes using the paired sample design and focused on their overlap to obtain a set of highly confident DE genes. First, using EdgeR, we excluded the genes that did not have one count per million reads in at least 50% of the samples. We normalized the read count values using trimmed means of M value and estimated common, trended, and tagwise dispersions using R software (version RX64 3.0.2). Together, these quality control steps removed genes with low expression and normalized the libraries for library size and biological variability, resulting in 14 816 genes for our subsequent analyses. We determined DE using the generalized linear model likelihood ratio test using a significance threshold of FDR <0.05.
Second, similarly as in EdgeR, we used a multifactor design with DESeq2. We estimated the size factors and dispersions and performed negative binomial generalized linear model fitting for the sample as a factor and Wald statistics for DE. We used Benjamini-Hochbergadjusted P<0.05 as a threshold for significance.
To compare the aSAH patients with aneurysm controls, we considered only the genes DE between the aSAH baseline and after the treatment. We performed 2 separate DE analyses using negative binomial and determined DE using Wald test for (1) the aSAH baseline group versus the controls and (2) the aSAH RIC treatment group versus the controls ( Figure I in the online-only Data Supplement). The genes changing the DE status between the 2 analyses (ie, the genes that were not DE between the aSAH baseline group and controls, but became DE when comparing the 
Methylation
We analyzed blood DNA methylation profiles by reduced representation bisulfite sequencing (RRBS). RRBS libraries from human genomic DNA were prepared as previously described. 19 Briefly, we treated blood DNA with sodium bisulfite (Epitecht Illumina), digested it with the MspI enzyme, and selected fragments averaging 100 to 250 bp. We multiplexed 4 samples per lane and sequenced the libraries using single-end 100-bp reads with the Illumina Hiseq2000 platform, resulting in on average 25.1 mol/L reads per sample.
We performed initial QC for fastq files using FastaQC. We used BS-seeker2 20 with Bowtie2 21 for RRBS alignment using hg19 as a reference genome. For alignment, we considered in silico MspI fragments between 40 and 500 bp to cover all possible MspI fragments from the RRBS libraries. We aligned the reads using the Bowtie2 end-to-end alignment mode by allowing 4 mismatches. We called the methylation status of the individual CpG sites (percentage of methylated cells) by requiring at least 10 reads per a CpG site. Pearson correlation coefficient was used to estimate pair-wise correlations in methylation sites between the individuals. Paired Students t-tests were conducted to compare between-group and within-group differences. The CpG sites passing a 2-tailed nominal P<0.01 were considered significant and carried forward for subsequent analyses. Finally, we used BEDTOOLS 22 to overlap the DE genes with methylated regions.
Functional Annotation and Coexpression of the Pathway Genes
We used DAVID software 23, 24 to search for functional categories of the DE genes. To highlight the most relevant gene ontology terms associated with the overlapped DE and differential methylation (DM) gene lists, we performed a batch annotation and gene-GO term enrichment analysis. We searched for protein-protein interaction (PPI) networks using STRING v9.1. 25 We used Pearson correlation coefficient to estimate correlations between the pathway genes and ggplot2 and reshape2 to visualize these results. Reactome 26, 27 was used to explore specific pathways.
Results
The overall study design is shown in Figure 1 . To identify genomic mechanisms for the effects of RIC in aSAH patients, we used a paired sample design where each patient gave blood samples before and after 4 RIC sessions. Using this longitudinal study design, each individual functions as a control for him-/herself in the DE and DM analyses. Accordingly, we were able to adjust for potential confounding factors, such as age, smoking, medication, and ethnicity, using this intraindividual paired design. We analyzed the blood RNA expression and DNA methylation profiles of each patient before RIC and 1 week after the RIC treatment started. We compared these profiles to the ones of the controls who did not receive any RIC treatments. Finally, we overlapped the DE genes with DM sites and performed functional annotations and PPIs analysis of the overlapping genes ( Figure 1 ).
Differential Expression
We found 451 DE genes after RIC (FDR<0.05) consistently using both EdgeR and DESeq2, of which 205 were upregulated after the RIC treatment and 246 were downregulated, respectively ( Figure 2 ; and Table I in the online-only Data Supplement). Next, to identify genes responding to the RIC treatment, we tested the expression of the 451 genes in the controls for DE against their expression at both the aSAH baseline and after the RIC treatment, considering a Bonferroni-corrected P<1.1×10 −4 (P<0.05/451 DE genes) significant. We found 164 DE genes (see Table II in the onlineonly Data Supplement for the list of DE genes) between the controls and aSAH patients before and after RIC treatment, suggesting that these genes may contribute to the response to the RIC treatment.
Differential Methylation
We were able to map on average 66% of reads/sample to the human genome, which is in accordance with previous RRBS studies. 20, 28 The resulting methylation profiles per sample covered on average 1 764 402 CpG sites, of which 676 543 were assayed in all individuals. The overall methylation status changed little within an individual (≈98%) and between individuals (≈97.5%; Figure II in the online-only Data Supplement), suggesting that methylation is a stable phenomenon and only a small number of sites are actively responding to environmental factors. We focused on the 403 546 CpG sites that altered by >10% in at least one individual after RIC. To test DM cytosines between the baseline and after treatment, we used 2-tailed paired student's t test. A total of 3493 CpG sites were DM (P<0.01). ) and for cell cycle and mitosis (B-Hcorrected P<3.8×10 −4 ; Table 2 ). In addition, we examined the PPIs of the 103 DE genes using String (Figure 3 ). We found a significant enrichment for PPIs and one large network consisting of 21 DE and DM genes (Figure 3 ), of which 14 are part of the cell cycle pathway from the functional enrichment analysis (Table 2 ). We also found 2 smaller PPIs consisting of 3 proteins each: CEBPB, HDAC4, PPARG and AZU1, CTSG, MPO (Figure 3 ), all present in the significant pathways of defense and inflammatory response mechanisms ( Table 2) .
Next, we further examined the 14 cell cycle pathway genes for correlations between their gene expressions. These genes exhibited highly dynamic correlation shifts, with substantially tighter correlations after the RIC treatment (Figure 4 ), suggesting that different phases of cell cycle pathway are turned on as a result of RIC. Interestingly, when we visualized the coexpression of these genes in the control group, we observed a clear difference in their correlations when compared with the aSAH patients at baseline and even more after the treatment (Figure 4) , indicating the involvement of these genes in aSAH and the potential influence of the RIC treatment.
Based on a more detailed Reactome pathway analysis (Table IV in the online-only Data Supplement), 8 of the 14 genes (FDR<1.0×10 −5 ) are involved in the cell cycle pathway (SPC24, ESPL1, CLSPN, CDC45, CENPF, FOXM1, CDK1, RAD51). In the Reactome analysis, CDK1 acts as a key regulator of specific mitotic cell cycle pathways. For instance, we observed that CDK1 is involved in G2/M transition and mitotic G2-G2/M phases with CENPF and FOXM1, regulating the G2/M checkpoints with CLSPN and CDC45. In addition, CDK1 is involved in processes such as kinetochore assembly in mitotic prometaphase and M Phase with SPC24, CENPF, and ESPL1 (Table IV in the online-only Data Supplement). CDK1 is also present in numerous activation and signaling pathways within mitotic cell cycle pathway (Table IV in the online-only Data Supplement).
Discussion
We performed the first longitudinal and systematic genome-wide pilot study in humans comparing gene expression and methylation changes after RIC in aSAH. We found 164 DE genes and 3493 DM CpG sites that are modified, potentially as a result of RIC. When we overlapped these regions, we observed 204 DM CpG sites corresponding to 103 DE genes, suggesting methylation as a potential mechanism regulating gene expression. These genes were enriched for cell cycle-related processes, as well as for defense and inflammatory responses. Furthermore, the identified 14 cell cycle genes exhibited highly correlated expression signals after RIC (Figure 4) . Overall, these findings provide first insights into the neuroprotective molecular mechanisms underlying RIC in humans.
Our prior work has demonstrated RIC-induced metabolic changes in the preconditioned limb, as well as cerebral tissue. 29, 30 Muscle microdialysis during RIC showed an increase in lactate/pyruvate ratio and lactate, without change in glycerol. 29 Cerebral microdialysis during RIC showed a decrease in lactate/pyruvate ratio and glycerol, which persisted after the last RIC session. 30 Identification of markers of the RIC effects beyond local factors is imperative for determining appropriate end points in future RIC clinical studies.
Whole-genome transcriptional analysis has been applied to uncover genetic changes underlying ischemia-induced B-H indicates P value after Benjamini-Hochberg correction for false discovery rate; and DE, differential expression. neuroprotective effects in animal models. 31, 32 DNA methylation changes of gene promoter regions have also been investigated to uncover preconditioning-induced epigenetic changes, contributing to neuroprotection in mice. 33 Although proof of concept animal studies have given great insight into the potential mechanisms of RIC, they do not necessarily translate directly to humans, and thus, human studies are essential to evaluate effects in clinical settings.
Cell cycle machinery and related molecules have been previously implicated in ischemic neuronal death, 34, 35 and irregular cell cycle activation has been implicated in stroke. [36] [37] [38] We show evidence for involvement of genes in cell cycle processes regulated by CDK1 in the acute stage of aSAH, possibly modified by RIC ( Figure 4 ). We postulate that this pathway may be important in various forms of ischemia. Furthermore, we hypothesize that RIC may induce a release of substances from the ischemic limb muscles to blood. These in turn stimulate white blood cells, such as macrophages, to increase the expression of genes involved in cell cycle and cell proliferation. Subsequently, these white blood cells may stream to the 
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ischemic location in brain and release substances, including growth factors and other cytokines, to protect brain from further apoptosis. This mechanism could lead to the neuroprotective effects of RIC, although additional functional studies are warranted to verify the underlying mechanisms. One of the mechanisms proposed for RIC is inflammatory responses. 39, 40 In accordance with this, our DAVID pathway analysis implicated a set of 18 both DE and DM genes in defense response pathways (CEBPB, AZU1, BPI, CTSG, CRISP3, CYSLTR1, HDAC4, INHBA, IL1R1, IL10RB, LTF, MPO, OLR1, PPARG, PROK2, STAT5B, STAB1, and TLR5). Six of these genes were also involved in 2 separate PPIs ( Figure 3) .
A recent study exploring human plasma proteome in RIC found that cysteine-rich secretory protein 3 (CRISP-3) was increased in serum after RIC in 6 adults. 41 This is consistent with our finding of over a 2-fold increase of CRISP3 gene expression in blood followed by RIC (Table I in the onlineonly Data Supplement), suggesting its role as a humoral RIC mediator and surrogate marker. CRISP-3 is a glycoprotein present in exocrine secretions, bone marrow, secretory granules of neutrophils, and plasma bound to a1B glycoprotein. 42, 43 Although its complete function is unknown, it is thought to act in innate immune response and as a prostate cancer marker. 42, 43 In summary, in this first pilot study, using a longitudinal design to investigate genome-wide expression and methylation changes in aSAH patients after RIC, we found evidence for coordinated expression and methylation changes of a small set of key genes in mitotic cell cycle, defense, and inflammatory responses. We have limitations in this study, and therefore, the results presented here should be further investigated and verified in future considerably larger genomic studies. In addition to the small sample size, we recognize that some of the observed changes in genes expression and methylation are potentially because of other medical treatments these patients received in the hospital, and hence, future studies should comprise a randomization that includes patients not receiving any RIC treatment as controls. We also recognize that differences in blood cell types may contribute to the changes in DNA methylation and gene expression, and thus future RIC studies should include analysis of separate fluorescence activated cell sorting-sorted cells. Nevertheless, longitudinal genome-wide studies of stroke, and especially SAH, integrating expression and methylation changes at the genome-wide level are still sparse, and thus our study provides valuable initial data, starting to elucidate the largely unknown mechanisms underlying RIC in humans.
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